Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

Table 6 Univariate and multivariate analyses of risk factors for tumor progression over time in matched-pair groups

Variables	Univariate analysis, P value	Multivariate analysis, P value
Treatment with CBZ vs REG	0.8851	-
NLR ≤ 3 vs > 3	0.00061	0.0006
CRP (mg/L) > 10 vs ≤ 10	0.03641	0.0624
ALP (IU) > 200 vs ≤ 200	0.5545	-
Bilirubin total (μmol/L) > 17 vs ≤ 17	0.02701	0.3262
Albumin (g/L) > 36 vs ≤ 36	0.3026	-
PT (%) > 70 vs ≤ 70	0.0534	-
AST (IU) > 45 vs ≤ 45	0.00481	0.0132
AFP (ng/mL) > 400 vs ≤ 400	0.0634	-

¹Included in multivariate analysis.

CBZ: Cabozantinib; REG: Regorafenib; NLR: Neutrophil-to-lymphocyte ratio; CRP: C-reactive protein; ALP: Alkaline phosphatase; PT: Prothrombin time; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein.